Lallemand Pharma

About Lallemand Pharma

Lallemand Pharma AG, is a company dedicated to the development and commercialization of respiratory products having the status of drug or medical device.
Since 2007, Lallemand Pharma markets drugs containing as an active principle, a bacterial lysate called PMBL®. Products are sold in several countries under different brands Ismigen®, Immubron®, Respibron® and PIR-05®. PMBL based products are Rx products indicated in the prevention and treatment of recurrent respiratory tract infections.
In 2018, Lallemand Pharma started to develop a line of nasal sprays also aiming at respiratory conditions.
The line of nasal sprays is called Healsea® and can be proposed either with a bag on valve technology or with manual spray pump. 

Certifications
  • CH
  • 2022
    On CPHI since
  • 3
    Certificates
  • 1 - 24
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Medical Devices
Contact info
Meet us at

CPHI Frankfurt 2022

Messe Frankfurt, Germany
1-3 November 2022

Products from Lallemand Pharma (1)

  • Ismigen®

    Product Ismigen®

    Indicated for the prophylaxis of the recurrent respiratory infections